Clinical Proof-of-Concept of a Non-Gene Editing Technology Using miRNA-Based shRNA to Engineer Allogeneic CAR T-Cells
International Journal of Molecular Sciences · 15.02.2025 · 26 (4) · 1658
DOI: 10.3390/ijms26041658 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.02.2025. Verfasst von Caroline Lonez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Celyad Oncology, 1435 Mont-Saint-Guibert, Belgium. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, MicroRNAs, Multiple Myeloma, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Celyad Oncology, Celyad Oncology SA.
Abstract (Originalsprache)
With the success of chimeric antigen receptor (CAR) T-cell therapy in B-cell malignancies, efforts are being made to extend this therapy to other malignancies and broader patient populations. However, limitations associated with the time-consuming and highly personalized manufacturing of autologous CAR T-cells remain. Allogeneic CAR T-cell approaches may overcome these challenges but require further engineering to reduce their alloreactivity. As a means to prevent graft-versus-host disease (GvHD) of allogeneic CAR T-cells, we have selected a micro RNA (miRNA)-based short hairpin RNA (shRNA) targeting CD3ζ which efficiently downregulates the expression of the T-cell receptor (TCR) below detection level. We generated allogeneic anti-B-cell maturation antigen CAR T-cells (CYAD-211) that co-express an anti-CD3ζ miRNA-based shRNA within the CAR construct which efficiently inhibited TCR-mediated signaling in vitro and GvHD in vivo. CYAD-211 was subsequently evaluated in a Phase-I clinical trial (NCT04613557), in patients with relapsed or refractory multiple myeloma. No signs of GvHD were observed despite evidence of engraftment, demonstrating efficient downregulation of the TCR. Our data provide proof of concept that a non-gene-edited technology can generate fully functional allogeneic CAR T-cells, without any signs of GvHD. However, further engineering of the CAR T-cells is needed to improve their persistence and long-term activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Celyad Oncology, 1435 Mont-Saint-Guibert, Belgium.
- Division of Hematology, University Hospital Antwerp (UZ Antwerp), 2650 Antwerp, Belgium.
ORCID-Profile: Caroline Lonez, Jennifer Bolsée, Sebastien Anguille, Eytan Breman
Förderung
- Celyad Oncology
- Celyad Oncology SA
Zitieren
APA
Lonez, C., Bolsée, J., Huberty, F., Nguyen, T., Jacques-Hespel, C., Anguille, S., Flament, A., & Breman, E. (2025). Clinical Proof-of-Concept of a Non-Gene Editing Technology Using miRNA-Based shRNA to Engineer Allogeneic CAR T-Cells. International Journal of Molecular Sciences, 26(4), 1658. https://doi.org/10.3390/ijms26041658
Vancouver
Lonez C, Bolsée J, Huberty F, Nguyen T, Jacques-Hespel C, Anguille S, et al. Clinical Proof-of-Concept of a Non-Gene Editing Technology Using miRNA-Based shRNA to Engineer Allogeneic CAR T-Cells. International Journal of Molecular Sciences. 2025;26(4):1658. doi:10.3390/ijms26041658
BibTeX
@article{Lonez2025,
author = {Lonez, Caroline and Bolsée, Jennifer and Huberty, Fanny and Nguyen, Thuy and Jacques-Hespel, Céline and Anguille, Sebastien and Flament, Anne and Breman, Eytan},
title = {Clinical Proof-of-Concept of a Non-Gene Editing Technology Using miRNA-Based shRNA to Engineer Allogeneic CAR T-Cells},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {4},
pages = {1658},
doi = {10.3390/ijms26041658}
}
EUVIMED